of next increase prescribing after for amongst continued Saqib. has diagnosed with OGSIVEO year Thank quarter, the outcomes previous unsatisfactory of adoption adults of those the patients interventions. third We're line amongst tumors. physicians you, desmoid community at prescribed Nearly consolidate $XX.X second physicians. in revenue, in strong XX% most centers as the OGSIVEO million excellence depth our and a over in in prescribing we seeing to representing therapy growth net its launch, therapy leadership into seen with generated systemic newly expand We've of the product also and quarter. an In seeking position and continued a their
were XXX period As we XXX-milligram a switched transition adherence. packs, expected, the the improve patients was which month patient and blister experience to and to the enhance as July developed of
to patients, the a packs in and we transition largely short-term now complete While of benefits the blister for the quarters, is of flat coming the across the for expect the doses. transition positive including to to see form some some this new need prescription pricing the impact new due product caused delays
In is therapies, seasonality patient some addition, and many impacted with new July. as starts experienced summer that we common in
month with were successively pleased representing September, our demand we strong return launch. each since and However, best in to performance see August
setting in in the show on life commercial by FDA-approved size OGSIVEO for desire new clinical our further symptomatic sustained the to positioned These Importantly, fourth and are the limited use, robust the reduction overall real-world consistent longer-term real-time discontinuations, long-term quarter expect will positive data experiencing treatment with of identification and execution therapy. be are growth in focused we make stay relief are are to contributing combined data and and DeFi, we our we quality that their in and patients from beyond. efforts, that which which is supported providing further improved seeing meaningful label, with tumor continued experiences, well patient us that confident benefit with
our patient we're now mark position a in the the of As metrics in of past from confidence our underscores some all learnings to increased share and key our we X-year launch, dynamics and in which magnitude approach prescribing the understanding and of commercial the year, opportunity.
OGSIVEO. population. over prescription I'll XXX filled for on September, patient patients First, touch In unique a the
As you might we've treatment durations clinical between years recall, X.X of observed X and our median trials. in
the still and the thus early of median believe too are be benefits low far what setting, support treatment will our follow-up While durations duration enable know are real-world discontinuation DeFi medicine. we in our that will and treatment data receiving new from life-changing pleased we long-term seeing the to to it's the continue rates patients extended of by
in them Now best treated given dose actively of total introduction the of number month greater on it's that us administration suited script patients dosing note into And the pricing, value to packs for exactly important gives and capture of packs not any time. filling the blister given the blister patient. number commensurate us all refill at underrepresents to the since of visibility patients The flat each patterns. a their allow also
the We're already the timing of and the refills of improve seeing adoption packs. blister predictability with
the pack reduced of patients pill compliance and are are As format of offers. and that on September, this of burden blister convenience, experiencing XX% the end product improved OGSIVEO approximately the
packs by to complete We the end the year. the the to of transition expect blister
number better patients before October with but gratified desmoid-specific under use market the of management year on was approximately surface, scratched of XX,XXX here's originally had why. right population that ICD-XX we opportunity in believe code, has we've of XXXX, prior Growing we launched increasing diagnosed they and a out to of U.S. were our the the our X,XXX size. overall active patients. informed only calculated that prevalent each the X,XXX FDA in patients to tumor approval our the serve, understanding Based We're which we've of analysis, the desmoid
patients August XX,XXX strongly under through markedly Through data. of approximately identified management active unique our already this of year, desmoid patients been was code tumor conservative. the estimate suggests earlier that diagnosis have This new
Although patient captured desmoid to making not treatment the team immediately, require transparency code afforded our active treatment codes enables reach they're decisions. these a by by prescribers as tumor-specific may every
any with been codes tumor-specific desmoid these adopted, that the know have ICD-XX also as fully is case yet not rollout. We new
accordingly to we estimates numbers revise the in and future. these we will So expect grow, continue will our
to on the community. Moving physician
of that centers excellence. quarter us XXX in earliest is OGSIVEO XX as adopters, the see at approximately Physicians systemic treatment therapy centers sarcoma As firmly for desmoid beyond and which care standard is end, centers. have these prescribed established provide at far a OGSIVEO, were of our data these our we centers tumors in approximately of
of to broaden these community been robust commercial demand, key awareness our outside our high allowed to us and execution, reach coupled goals reach with our to patients centers, of One has and physicians has and positions. strong
OGSIVEO of the stands setting. prescribers today, XX% in it As practicing are community
FDA coverage the approval has to OGSIVEO, of area remains have an to payer broad and able been packs. our and it robust they strong with patients been reimbursement. efficiently due blister strong introduction since of When strength are prescribed the Lastly, access
most our that we attributes. OGSIVEO's and perform perspective, ask The translates number off to positive of the intent of see to notably positive across In prescribe. feedback well quality an far Our a profile in physicians this you chart, On has tolerability, they overall to also efficacy feedback on OGSIVEO along started treatments improvements research, dimensions only important physician physicians pain market strong attribute, on outperforms can improve. continued every from of from how and use the but life.
said of Specifically from OGSIVEO that approximately a surveyed likely use frontline XX% as they're treatment. to research, our prescribers
expect Second, expect using our year. growth this to increase OGSIVEO, them Collectively, their surveyed the research ahead. potential of also about not indicates the but physicians that coming nearly only usage continue all XX% for in to strong supports
to overall of tumors, intervene share when our desmoid urgency to underpin that progression. in further to the the tumor towards treat some like sign how to dynamics now with treatment would evolving at with which confidence for I desmoid opportunity, patients point earliest and starting attitudes the
over increasing with require active therapy who favors levels treatment, for patients which alignment guideline-based seeing We're systemic of surgery treatment.
However, initiating based we progression. also on clinical of on treatment a a evidence observed radiographic progression, not growing have range symptoms of recently, only of prescribers emphasis more
symptomatic of for fact, without use radiographic In OGSIVEO patients progression. likelihood XX% to physicians surveyed indicated
XX% continue considered this factors worsening treat. As in pain, and at drive than slide, expect shown these view on is of function this symptoms time view and as decline to Each doctors the or to treatment. last responses sentiment treating new saw XX% will community the overall initiating that and year, amongst XX% we urgency grow worsening for higher we what of
radiographic covers or As symptomatic based a progression. either reminder, OGSIVEO's treatment label on
landscape So with patients earlier this in for course disease. treatment candidates become will expect their OGSIVEO shifting that dynamics, we of more the
outside to also make the important bring patients approval in currently we and marketing In the U.S. our continue year. EU, to half first We progress the application of under is next review, OGSIVEO authorization anticipate to
well launches. liaisons, and and Our and of conducting the a markets market we've in comprehensive to members commercial with onboarded. with to in headquarters To facilitate pricing medical established medical successful Germany of European leadership work team other also to being expand begin countries. key access We're key and efforts, support for Switzerland these and each as process launch these science hired personnel plan is of European in the as series EU other then field
U.S. The that opportunity successful an of with to see of characteristics number launch. desmoid European number a tumor the that are a conducive us, for We market proportionate patients a represents to attractive in
need the are access limited, broad. recognize currently is prescribers no unmet that First, available and treatment off-label EMA-approved therapies with are treatments given there high to options, which not
selected treatment is surgery of is European while countries. for desmoid some considered it tumors some for frequently less in the patients, Further,
prescribe high therapies. indicates approval that potential to work offered benefits likely for enthusiasm believe by survey XX% clinical a and oncologists blinded profile, not Our other more offers of OGSIVEO. Based the OGSIVEO than on of are
finally, already our with active program, leaders the through as Importantly, than several OGSIVEO And DeFi have efficient centralized tumors Europe, of opinion sites relatively as which through of experience more in desmoid well compassionate is is XXX commercial use and enabling use footprint. the care patients. an key
we the over several the months, PMDA Turning to briefly expect the successful and to preceding year. Japan. discussions We've study next course initiate with of bridging had a
date confident performance pleased to ahead the very the growth are commercial and us grow of opportunity We with a U.S. for basis. OGSIVEO on significant in are in the of
on few To a than patient on large is growth, original is of increasing as a that treatment which treatment across tailwinds to strong recap guidelines, just strong the well with there life shift based preference systemics towards OGSIVEO. quality for larger supporting criteria, based estimates, with symptoms a of radiographic benefits rather data growing continued initiating OGSIVEO propensity of use and our long-term continued efficacy, support safety and as and physician population, durable metrics treat than
many years that We patients of changing ahead. to is gratified OGSIVEO the and forward patients with months lives are look tumors and serving the desmoid more in
mirdametinib. Turning now to
living a ] profound are tumors of disease. the disfigurement, sheets a neurofibromas, chronic lifetime families plexiform with and NFX. to XX,XXX are living death patients pain on are are are severe nerve adults [ in There that there These excited We XXX,XXX not do significant United approximately highly debilitating people XX% and of NFX-PN therapy. an about in States who estimate and ahead approximately the developing functional with have whom of opportunity this along have today, We XX% that FDA-approved make the risk to cause with impairment. which and individuals patients impact U.S. currently grow lives can us very XX% of peripheral
the number United are As people well. NFX-PN disease, there with this of demographic leaning a no as for outside specific proportionate estimate States we that living is there of
MEK have approved treatment landscape treatment formal as patients highly therapies, guidelines an even no is standard inhibitors for off-label of significant there of for currently medicine. care, validated whom a use treatment While a there of class pediatric NFX-PN, no emerged and is for fragmented with
that NFX community a market patients desperately with that is targeted only this need options. been treated portion research and of small new of in shows Our a have therapy
both this support therapy the Data from and ReNeu meeting, at to will potential children a ASCO be our presented Neuro-Oncology that Phase that differentiated mirdametinib's and confirmed also presented but share will responses, robust central few be year a the important The which in the a with were pediatric adults significant in moments, emphasize believe blinded weeks few trial Society only data size both differentiator tumors, of NFX-PN. for independent These with across we objective and robust us. response an reductions PN adult not show IIb in results the efficacy Jim ReNeu trial at which rates by results deep cohorts. represent for additional review, of very
experienced morbidities. to In since, and These of significant of is in and in addition, outcomes sustained the and course with life treatment very cases, over of including meaningful improvements adults goal their pain. quality reductions other treatment clinically both children early primary improve in mirdametinib, pain PN-associated many health-related are
AEs. with low due low believe a the to We Mirdametinib disease in profile therapy. NFX-PN, also potential like important events there chronic is demonstrated stopping high for where recurrence rates children in adverse Grade X rates of after are related a and and which manageable adults, tolerability both durations, treatment supports rates extended discontinuation safety profile of mirdametinib's
are marketing believe that authorization and enhance regimen, our mirdametinib's a Lastly, holiday convenient under built-in provides ahead we pediatric-friendly by optimize NDA preparations. review a and we tablet the further our experience for With moving with potentially EMA, dosing steam priority treatment oral validated patient which accepted suspension, the compliance. commercial dispersible could and application full
commercial thoroughly years NFX-PN. treating the from patients the We OGSIVEO physicians important with collecting and are working to We've spent successful leveraging critical disease therapy. needs learnings These to past efforts and have patient our had infrastructure on several launch community. the from serve of who been behalf approved have this especially patients an insights and caregiver face to the without adult devastating NFX-PN of understand
engagement has isn't Care, for received engage from and campaign Our to disease on This feedback advocate high and positive and empowering young alike. state education physicians and adult campaign, Coping in entitled treatment. patients educating ongoing patients themselves focuses to
other all in a data also safety on focuses launch based plan differentiate our efficacy of aspects and patients that on developed robust We've systemic mirdametinib the that ages. treatments from
As we therapy. through program, Connection patient tumors, and eligible with ensure those did support Care with offer the designed we have to NFX-PN will for our SpringWorks services needs of patients unique access that desmoid is comprehensive patients which to
many sales experience training We've centers and which our ReNeu from field Their our with NF started also the on of representatives. mirdametinib be of team, have will the focus hired States, consists XX-or-so United network across XX as well trial comprehensive patient initial which enable physicians be patients academic them to will with are NFX-PN. data currently target and identification setting. managing teams treatment with community with who as other both sites to assist the equipped These key resources and and clinical in
by to share commercial incredibly We are ahead PDUFA we the plans and excited we our NFX-PN will date. us XX serve patients, more to on as opportunity our of closer get February
Jim With Jim? emerging over that, call recent provide our pipeline discuss on I'll highlights data update turn an and the programs. to to
